Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

NCT05040360 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT05040360
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05040360 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
May 5, 2022
Completion date
March 31, 2027
Enrollment
141 (estimated)
Sites
448

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm in the liver, pancreatic neuroendocrine tumor, stage i pancreatic neuroendocrine tumor ajcc v8, stage ii pancreatic neuroendocrine tumor ajcc v8, stage iii pancreatic neuroendocrine tumor ajcc v8